India Human Papillomavirus Vaccine Market Size 2025: Share, Growth Analysis & Industry Report 2033 | Get Free Sample

According to IMARC Group’s report titled "India Human Papillomavirus Vaccine Market Research Report and Industry Forecast" the report offers a comprehensive analysis of the industry, including market share, growth, trends, and regional insights.

India Human Papillomavirus Vaccine Market Overview

The India human papillomavirus vaccine market size reached USD 0.28 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 1.05 Billion by 2033, exhibiting a growth rate (CAGR) of 15.55% during 2025-2033. The rising awareness regarding cervical cancer, government immunization programs, and increased affordability owing to domestic vaccine production are key growth drivers.

India Human Papillomavirus Vaccine Market Key Takeaways

• Current Market Size: USD 0.28 Billion in 2024
• Forecast Period: 2025-2033
• CAGR: 15.55%
• The Indian government’s inclusion of HPV vaccination in the Universal Immunization Program aims to vaccinate girls aged 9 to 14, targeting nearly 80 million beneficiaries over three years.
• Cervical cancer remains the second-most prevalent cancer among Indian women with approximately 125,000 new cases and 75,000 deaths annually.
• Launch of the indigenous quadrivalent HPV vaccine, CERVAVAC, by Serum Institute of India in 2023, has significantly reduced vaccine prices, boosting adoption.
• Government negotiations set CERVAVAC's price at INR 200-250 per dose, nearly one-tenth of previous vaccines' retail prices.
• Domestic production improves vaccine accessibility, affordability, and supply stability.

Note : We are in the process of updating our reports to cover the 2026–2034 forecast period. For the most recent data, insights, and industry updates, please click on ‘Request Free Sample Report.

Request Free Sample Report: https://www.imarcgroup.com/india-human-papillomavirus-vaccine-market/requestsample

India Human Papillomavirus Vaccine Market Growth Factors:

• Rising awareness regarding cervical cancer prevalence and preventive vaccination.
• Government immunization programs such as the integration of HPV vaccine in the Universal Immunization Program.
• Increased affordability due to domestic production of vaccines like CERVAVAC.
• Growing healthcare infrastructure supporting immunization activities.
• Support from international organizations such as WHO boosting vaccination efforts.
• Push for adolescent vaccination to reduce cervical cancer incidence.
• Stable supply chains ensured by reduced reliance on international suppliers.
• Public-private partnerships enhancing vaccine development and distribution.
• India's commitment to the 'Make in India' initiative driving domestic vaccine innovation.

India Human Papillomavirus Vaccine Market Trends:

• Inclusion of HPV vaccination in India’s Universal Immunization Program announced in the 2024 Union Budget.
• Target vaccination for girls aged 9-14 through schools and primary health centers.
• Use of quadrivalent HPV vaccine providing protection against HPV types 6, 11, 16, and 18.
• The government's approach emphasizes early vaccination to reduce cervical cancer burden.
• Launch of India's first indigenous quadrivalent HPV vaccine, CERVAVAC, in January 2023.
• CERVAVAC introduced through collaborations of Serum Institute of India, DBT, BIRAC, and Bill and Melinda Gates Foundation.
• Significant price reduction with CERVAVAC priced between INR 200 and INR 250 per dose versus prior vaccines costing INR 2,000 to INR 4,000 per dose.
• Increased adoption likely in rural and low-income regions due to affordability.
• Domestic vaccine production reduces foreign dependency, ensuring supply stability.

India Human Papillomavirus Vaccine Market Segmentation:

Valence Insights:

• Bivalent
• Quadrivalent
• Nonvalent

The market is segmented based on vaccine valence including bivalent, quadrivalent, and nonvalent vaccines to cater to different HPV strains.

Disease Indication Insights:

• Cervical Cancer
• Anal Cancer
• Vaginal Cancer
• Penile Cancer
• Vulvar Cancer

The market covers multiple disease indications, primarily cervical cancer along with anal, vaginal, penile, and vulvar cancers.

Distribution Channel Insights:

• Hospitals and Clinics
• Governmental and Non-Governmental Organizations
• Public and Private Alliances

Distribution channels include healthcare institutions, governmental and non-governmental organizations, and various alliances.

Regional Insights

• North India
• South India
• East India
• West India

The South Indian region holds a dominant position in the market, contributing the largest share with a robust growth trajectory at a CAGR of 15.55% during 2025-2033. Other regions including North, East, and West India also offer significant growth opportunities.

Buy the Latest 2026 Edition: https://www.imarcgroup.com/request?type=report&id=32620&flag=C

Recent Developments & News:

• April 2025: Tens of thousands of medical professionals began receiving specialized training nationwide to promote the HPV vaccine and cervical cancer prevention, supported by the Federation of Obstetric and Gynecological Societies of India (FOGSI) and partly funded by Cancer Research UK.
• March 2025: Pune Municipal Corporation initiated an HPV vaccination program for girls in Classes 8 and 9 in municipal schools starting June 2025, collaborating with NGOs and utilizing Corporate Social Responsibility (CSR) funds to subsidize costs.

Key Highlights of the Report:

• Comprehensive quantitative analysis of market segments, trends, and forecasts from 2019-2033.
• Exploration of market drivers, challenges, and opportunities.
• Porter's five forces analysis detailing competition and market attractiveness.
• Detailed competitive landscape with company profiles and evaluation.
• Segmentation by valence, disease indication, and distribution channel for targeted insights.

Competitive landscape:

The report offers an in-depth examination of the competitive landscape, including market structure, key player positioning, leading strategies for success, a competitive dashboard, and a company evaluation quadrant.

Get Your Customized Market Report Instantly: https://www.imarcgroup.com/india-human-papillomavirus-vaccine-market/customize

Note: If you require any specific information not covered within this report’s scope, we will provide it as part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps ambitious changemakers create a lasting impact. The company offers comprehensive market assessment, feasibility studies, incorporation support, regulatory assistance, branding and strategy services, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel: (D) +91 120 433 0800

United States: +1-201971-6302